Transgenomic, Inc. (TBIO) Completes Acquisition of ScoliScore™ Prognostic Scoliosis Test
9/24/2012 9:18:10 AM
OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO) announced today that it has closed the previously announced acquisition of Axial Biotech’s ScoliScore™ Adolescent Idiopathic Scoliosis (AIS) Prognostic Test for a total consideration of $4.4 million in cash. The acquisition provides Transgenomic with the ScoliScore™ assay technology and intellectual property, an established revenue and customer base, and access to a testing market estimated at 400,000 patients in the United States alone.
comments powered by